Celldex Therapeutics (CLDX) Other Non-Current Assets (2010 - 2026)

Celldex Therapeutics' Other Non-Current Assets history runs 17 years deep, the most recent figure standing at $15.4 million for Q1 2026.

• In Q1 2026, Other Non-Current Assets rose 48.28% year-over-year to $15.4 million; the TTM figure through Mar 2026 stood at $15.4 million (up 48.28% YoY), while the FY2025 annual figure was $13.4 million, up 37.05% from the prior year.
• Other Non-Current Assets was $15.4 million for Q1 2026 at Celldex Therapeutics, up from $13.4 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $15.4 million in Q1 2026 to a low of $104000.0 in Q1 2022.
• Historically, Other Non-Current Assets has averaged $4.6 million across 5 years, with a median of $107000.0 in 2023.
• Biggest YoY gain for Other Non-Current Assets was 9628.04% in 2025; the steepest drop was 3.93% in 2025.
• A 5-year view of Other Non-Current Assets shows it stood at $104000.0 in 2022, then climbed by 2.88% to $107000.0 in 2023, then jumped by 9009.35% to $9.7 million in 2024, then jumped by 37.05% to $13.4 million in 2025, then rose by 15.54% to $15.4 million in 2026.
• The last three Other Non-Current Assets figures came in at $15.4 million (Q1 2026), $13.4 million (Q4 2025), and $9.4 million (Q3 2025), per Business Quant data.